Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the TheraVance Biopharma third quarter 2025 conference call. During the presentation, all participants will be in a listen-only mode. A question and answer session will follow the company's formal remarks. To ask a question, press star 11 on your telephone. If listening via webcast, please mute audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference call is being recorded. And now I'd like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir. Good afternoon, and welcome to Theravance Biopharma's third quarter 2025 earnings results conference call. On slide two, you'll find our forward-looking statements disclaimer, which covers certain risk factors which could cause actual results to differ materially from any forward-looking statements we might make in today's call and which are described further in our filings with the SEC. Moving to slide three, I'm joined today by Rhonda Farnham, Chief Business Officer, Anya Miller, Head of Development, and Aziz Sawaf, Chief Financial Officer. Turning to slide four, TheraVance delivered strong results in the third quarter, reflecting continued execution across the business and notable progress toward our strategic objectives. We achieved several key accomplishments, including solid upelry net sales growth and record brand profitability, leading to the achievement of non-gap break-evens. underscoring the strength of our business model and commitment to financial discipline. In parallel, we continue to advance the pivotal Phase III Cypress trial of Amproloxatine towards a data readout in early 2026, a milest...